Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
"A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 3"	Eli Lilly	Completed	Mirikizumab	3	I6T-MC-AMAP	King Fahad Specialist Hospital (Dammam)
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease	Celgene	Ongoing	Ozanimod HCl	3	RPC01-3204	KAUH-J
"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus"	MSD	Ongoing	Ertugliflozin	3	MK-8835-059-00	KSH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” Trial	Celgene	Completed	Luspatercept (ACE 536)	3	ACE-536-B-THAL-001	KKUH
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.	Eli Lilly	Terminated	Prasugrel	3	H7T-MC-TADO	KAUH-J
A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF 06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE	Pfizer	Completed	PF-06651600	2a	B7981007	NGHA-R,KKUH, King Abdulaziz Medical City NG (Jeddah)
"A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease "	Janssen-Cilag International NV	Ongoing	Guselkumab	2	CNTO1959CRD3001	KAMC
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care	Kaleido Biosciences	Completed	KB195	2	K020-218	KKUH
A Phase 1/2 Open-label Clinical Study of hLB-001 Gene Therapy in Pediatric Patients With Methylmalonic Acidemia Characterized by MMUT Mutations	Logic Bio Therapeutics	Ongoing	AAV-hHA-hMUT	1, IIIb	LB001-001	King Abdulaziz Medical City NG (Riyadh)
A PARTIALLY DOUBLE-BLINDED, RANDOMIZED, CONTROLLED, PLACEBO-CONTROLLED STUDY, A PHASE III TRIAL OF SAFETY AND EFFICACY OF PREMEDICATION WITH DEXMEDETOMIDINE AND MIDAZOLAM IN PEDIATRIC PATIENTS	King Faisal Specialist Hospital and Research Centre	Ongoing	DEXMEDETOMIDINE	3	RAC# 21901310	King Faisal Specialist Hospital and Research Center (Riyadh)